Overview
- A PNAS study by Karolinska Institutet and Lund University shows that inhibiting PRDX6 and GSTP1 causes some tumor cells to die and others to differentiate into active neurons in mice.
- Current retinoic acid differentiation therapy fails in about half of patients, highlighting the need for alternative strategies.
- High PRDX6 and GSTP1 levels in neuroblastoma correlate with poorer survival, identifying these enzymes as promising treatment targets.
- One of the inhibitors holds orphan drug designation from the US FDA, potentially speeding its development for pediatric use.
- Researchers aim to launch clinical trials to assess the treatment’s safety and efficacy in children with neuroblastoma.